GLP-1受体信号通过抑制RAGE诱导的炎症减轻糖尿病肾病
本研究探讨GLP-1受体激动剂肾脏保护机制是否依赖RAGE。GLP-1受体敲除小鼠肾脏表型异常,糖尿病加重,共敲除RAGE可改善。利拉鲁肽下调肾脏RAGE、减少骨髓髓系祖细胞扩增、促进M2样巨噬细胞极化并减轻肾损伤标志物,单细胞转录组揭示其细胞特异性转录变化。
要点
- GLP-1受体缺失导致肾脏异常表型,糖尿病加速,共敲除RAGE可改善
- 利拉鲁肽下调肾脏RAGE并减轻糖尿病小鼠肾损伤
- 利拉鲁肽肾脏保护作用在非糖尿病慢性肾病模型中也得到验证
核心结论
- GLP-1基于疗法的肾脏保护作用部分通过抑制RAGE诱导的炎症实现,且不依赖降糖。
研究设计与样本
- 研究使用GLP-1受体敲除小鼠、糖尿病小鼠模型及亚全肾切除大鼠慢性肾病模型。
- 采用单细胞转录组学分析利拉鲁肽对肾脏细胞转录的影响。
主要发现
- GLP-1受体敲除小鼠出现肾脏表型异常,糖尿病加速该异常,共敲除RAGE可改善。
- 利拉鲁肽下调糖尿病小鼠肾脏RAGE,减少骨髓髓系祖细胞扩增,促进M2样巨噬细胞极化,减轻肾损伤标志物。
- 单细胞转录组显示利拉鲁肽诱导内皮细胞、近端小管细胞、足细胞和巨噬细胞转录变化,富集于营养转运、氧化还原感知和炎症消退通路。
- 利拉鲁肽肾脏保护作用在亚全肾切除大鼠慢性肾病模型中得到验证。
临床怎么用
- GLP-1受体激动剂可能为糖尿病肾病提供不依赖降糖的肾脏保护,机制涉及抑制RAGE炎症通路。
局限性
- 研究主要基于动物模型,临床转化需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glucagon like peptide-1 (GLP-1) is a hormone produced and released by cells of the gastrointestinal tract following meal ingestion. GLP-1 receptor agonists (GLP-1RA) exhibit kidney-protective actions through poorly understood mechanisms. Here we interrogated whether the receptor for advanced glycation end products (RAGE) plays a role in mediating the actions of GLP-1 on inflammation and diabetic kidney disease. Mice with deletion of the GLP-1 receptor displayed an abnormal kidney phenotype that was accelerated by diabetes and improved with co-deletion of RAGE in vivo. Activation of the GLP-1 receptor pathway with liraglutide, an anti-diabetic treatment, downregulated kidney RAGE, reduced the expansion of bone marrow myeloid progenitors, promoted M2-like macrophage polarization and lessened markers of kidney damage in diabetic mice. Single cell transcriptomics revealed that liraglutide induced distinct transcriptional changes in kidney endothelial, proximal tubular, podocyte and macrophage cells, which were dominated by pathways involved in nutrient transport and utilization, redox sensing and the resolution of inflammation. The kidney-protective action of liraglutide was corroborated in a non-diabetic model of chronic kidney disease, the subtotal nephrectomised rat. Thus, our findings identify a novel glucose-independent kidney-protective action of GLP-1-based therapies in diabetic kidney disease and provide a valuable resource for exploring the cell-specific kidney transcriptional response ensuing from pharmacological GLP-1R agonism.
引用
- Sourris KC, Ding Y, Maxwell SS, et al. Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation. Kidney Int. 2023. PMID: 38069998. doi:10.1016/j.kint.2023.09.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。